Aigen Investment Management LP Buys Shares of 5,959 Haemonetics Co. (NYSE:HAE)

Aigen Investment Management LP bought a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,959 shares of the medical instruments supplier's stock, valued at approximately $479,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HAE. Quarry LP purchased a new position in Haemonetics in the 2nd quarter worth about $39,000. Covestor Ltd increased its position in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 438 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in Haemonetics in the second quarter worth about $82,000. Canada Pension Plan Investment Board purchased a new stake in shares of Haemonetics during the second quarter valued at $83,000. Finally, EntryPoint Capital LLC bought a new position in Haemonetics in the 1st quarter worth about $86,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HAE. Barrington Research reissued an "outperform" rating and issued a $108.00 price objective on shares of Haemonetics in a research note on Friday, November 8th. BTIG Research began coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 target price on the stock. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective for the company in a research note on Friday, November 8th. JMP Securities reaffirmed a "market outperform" rating and set a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $112.00 price objective on shares of Haemonetics in a report on Friday. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $107.88.

Haemonetics Stock Down 1.7 %

Shares of HAE stock traded down $1.51 during trading hours on Friday, reaching $89.24. 564,400 shares of the stock were exchanged, compared to its average volume of 555,780. The business's fifty day moving average is $77.23 and its two-hundred day moving average is $82.77. The firm has a market capitalization of $4.48 billion, a P/E ratio of 37.01, a P/E/G ratio of 1.43 and a beta of 0.32. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company's revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.99 earnings per share. As a group, research analysts expect that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.